Related references
Note: Only part of the references are listed.Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer
Olga Kantor et al.
NPJ BREAST CANCER (2020)
Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer
Stephanie M. Wong et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis
Marissa K. Srour et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach
Anna Weiss et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study
G. Martelli et al.
EJSO (2017)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano et al.
ANNALS OF ONCOLOGY (2017)
Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases
T. J. A. van Nijnatten et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial
A. Savolt et al.
EJSO (2017)
Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment
V. Galimberti et al.
EJSO (2016)
The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis
Chong Geng et al.
PLOS ONE (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
Jean-Francois Boileau et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
Judy C. Boughey et al.
ANNALS OF SURGERY (2014)
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
Mila Donker et al.
LANCET ONCOLOGY (2014)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
Thorsten Kuehn et al.
LANCET ONCOLOGY (2013)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of Occult Metastases on Survival in Node-Negative Breast Cancer
Donald L. Weaver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag et al.
LANCET ONCOLOGY (2010)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients
Kelly K. Hunt et al.
ANNALS OF SURGERY (2009)
The National Cancer Data Base: A powerful initiative to improve cancer care in the United States
Karl Y. Bilimoria et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
David N. Krag et al.
LANCET ONCOLOGY (2007)
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: A pilot study
T Aihara et al.
JOURNAL OF SURGICAL ONCOLOGY (2004)
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation
B Fisher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
